[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma]

Combination chemotherapy with irinotecan and CBDCA was performed for two patients in the terminal stage of ovarian carcinoma. Every week, 75 mg.m-2 of irinotecan and 75-100 mg.m-2 of CBD CA were intravenously administered. Both patients showed a partial response. Diarrhea was not a characteristic side effect of irinotecan in this case. Dose limiting factors were leucopenia and thrombocytopenia.